Gem Aromatics Limited

Q&A

Q1: What drove the year-on-year revenue growth in Q1 FY27 despite seasonality, and which geographies are seeing strong demand in the core business?

A: Demand is returning to normal levels. Although Q1 is historically a softer quarter because the core mint season begins around May/June, demand is ramping up in the Western Hemisphere primarily the US and Latin America. These export sales and deal flows will reflect in Q2 and Q3 numbers. Standalone revenue reached ₹83 crore (up from ₹76 crore in Q1 FY26), while consolidated revenue stood at ₹99 crore (up from ₹88 crore).

Q2: What caused the supply disruption and raw material delays in the Clove business during Q1?

A: In March and April, Madagascar—where we source our raw material—experienced severe flooding caused by a major cyclone. This led to a 30-day shutdown at the main port of Toamasina, severely delaying raw material shipments and creating a temporary slowdown in incoming supplies. Port operations resumed around May, and material flow has since normalized.

Q3: What impacted the company’s consolidated margins and profitability, resulting in a loss for the quarter?

A: On a consolidated basis, gross profit was ₹16.5 crore (16.7% margin), EBITDA was ₹3.3 crore (3.3% margin), and net loss stood at ₹7.9 crore. Margins were primarily hit by product mix, higher raw material costs in the clove segment due to Madagascar disruptions, and higher operating costs at the new Dahej plant. Profitability was further affected by ₹9.1 crore in depreciation following the capitalization of the Dahej facility.

Q4: How much total capex has been incurred for the Dahej facility under the subsidiary Crystal Ingredients?

A: Of the total planned capex of approximately ₹270 crore for the Dahej facility under Crystal Ingredients Private Limited, nearly ₹265 crore has already been incurred and substantially capitalized.

Q5: What is the current status and revenue expectations for the Safranal / Citral-based product line?

A: Commercial production of Safranal has commenced, and the product is going through customer approval and qualification phases. Initial revenue contributions are expected towards the end of Q2 FY27, with more meaningful, scaled-up commercial orders coming through in Q3 FY27.

Q6: What progress has been made in the Cooling Agents vertical (GEMCOOL series)?

A: Production for GEMCOOL-3, GEMCOOL-5, and GEMCOOL-23 has commenced. Customer audits are complete, and we have been approved by two of the world's largest consumer companies in this segment. Initial orders have been secured, and recurring commercial supply scale-up is expected to yield meaningful revenue contributions starting in Q3 FY27.

Q7: What is the timeline for trial and commercial production of Phenol Derivatives?

A: Trial production for phenol derivatives is scheduled for the end of Q2 FY27. Commercial production for exports will start during Q3 FY27, following customer quality processes and approvals. Meaningful revenue contribution is expected to roll out in Q4 FY27.

Q8: What long-term strategy is the company executing to move away from traditional product dependencies?

A: A major part of our long-term strategy is reducing dependence on the traditional mint portfolio and shifting toward higher-value, non-mint specialty products, including cooling agents, safranal, and phenol derivatives. Our multipurpose platform at Dahej provides flexible chemistries to develop higher-value specialty molecules supported by a strong R&D pipeline.

Q9: Did the Madagascar floods permanently damage clove tree cultivation or create a structural raw material deficit?

A: No structural challenges are expected. Since we extract clove oil from the leaves and stems, trees usually recover within 2 to 3 years even if affected. Furthermore, production in Madagascar was not destroyed, and we maintain geographically diversified sourcing across Madagascar and East Africa. The primary issue was a temporary port backlog, which has now been resolved.

Q10: Why was there a strategic decision to set up a Brazilian subsidiary?

A: The Board approved the incorporation of a Brazil subsidiary to expand GEM’s distribution reach in Latin America. This creates a dedicated regional platform for direct marketing and distribution of our essential oils, aromatic chemicals, and specialty chemicals.

Q11: How do you expect Crystal Ingredients (the new verticals) to contribute to overall group revenues in FY28?

A: FY27 is primarily a ramp-up and product qualification year. However, by FY28, as commercial scale-ups complete, products from the Crystal Ingredients unit are expected to contribute more than 50% of the total consolidated revenue.

Q12: How will the working capital cycle for Crystal Ingredients differ from the core GEM business?

A: Since Crystal focuses on synthetic and specialty products, it will not require holding inventory for long durations, unlike the agricultural/traditional mint and clove businesses. Combined with the use of factoring services to shorten debtor days, the working capital cycle for Crystal will be significantly lower than that of the traditional GEM business.

Q13: Why did restocking demand from Q4 FY26 tariff reliefs not translate into stronger Q1 FY27 financial results?

A: The order flow and production did occur during May and June, but global shipping challenges out of India and export destination delays prevented several shipments from reaching customers before the end of Q1. Because these export shipments could not be accounted for as completed sales in Q1, the revenue realization has rolled over into Q2 and Q3.

Q14: Does foreign currency depreciation create a net pricing/competitive advantage for GEM's export business?

A: Currency movements do not provide a major tactical advantage or disadvantage. For several product lines (such as Clove and Phenol), raw materials are imported, processed in India, and then re-exported under foreign contracts. Consequently, the import costs and export realizations balance out.

Strategic Outlook

1. Management is focused on progressively scaling and monetising the expanded Dahej manufacturing platform, with improving capacity utilisation and a higher contribution from specialty products expected to support margin recovery.
2. The company expects to scale newer product categories through Krystal Ingredients, with cooling agents contributing from Q3FY27, Safranal gaining traction from Q2/Q3FY27 and phenol derivatives expected to contribute from Q4FY27.
3. Management continues to prioritise process innovation, product customisation and development of higher-value specialty molecules to strengthen product capabilities and improve the overall business mix.
4. The company plans to deepen its international presence through the proposed Brazil subsidiary, while the strategic location of Dahej near ports is expected to support faster exports and greater penetration into global markets.
5. Continued investment in R&D, technology upgrades, catalyst development and advanced green chemistries is expected to support new product development, process efficiencies and differentiated offerings.
6. Management remains focused on disciplined execution and sustainable value creation, while the normalisation of Madagascar’s clove supply situation is expected to provide a more stable operating environment going forward.

Business Strategy

1. The company is progressively shifting its portfolio towards advanced and specialty molecules across mint, clove, citral chemistry and phenol derivatives, with a focus on increasing the contribution of value-added products.
2. Gem Aromatics is leveraging its Dahej facility to manufacture cooling agents, phenol derivatives, Safranal, Damascone and Eugenol derivatives, supported by backward and forward integration for greater process control and product customisation.
3. The company continues to strengthen its core mint and clove businesses by leveraging its presence in the Budaun mint belt and expanded Dahej capacity to improve sourcing, domestic reach and export penetration.
4. R&D remains focused on improving yields, selectivity and process efficiencies, while developing new molecules and derivatives and identifying products with high demand and limited global competition.
5. The multipurpose capabilities at Dahej provide flexibility to address customer requirements and support CRO, CMO and CDMO opportunities, while enabling development of specialty and super-specialty products.
6. The company is expanding its international customer base through exports, serving 240 domestic and 44 international customers across 20 countries, while the proposed Brazil subsidiary is expected to strengthen its distribution reach in Latin America.

Key Highlights

1. Consolidated revenue from operations increased 12.80% YoY to ₹98.85 crs in Q1FY27, while standalone revenue grew 8.6% YoY to ₹83.0 crs despite the seasonally softer quarter.
2. Consolidated EBITDA margin declined to 3.31% from 14.86% YoY, impacted by product mix, higher raw material and operating costs, and ₹9.1 crs of incremental depreciation following capitalization of the Dahej capex.
3. The company has capitalised ₹265 crs of the planned ₹270 crs Dahej capex, with the expanded manufacturing platform expected to support higher-value products and improve margins as utilisation increases.
4. Customer audits for GEM Cool 03, GEM Cool 05 and GEM Cool 23 have been completed and initial orders secured, with revenue contribution expected from Q3FY27. Safranal and phenol derivatives are also progressing towards commercialisation.
5. The company approved incorporation of a wholly owned subsidiary in Brazil to distribute essential oils, aromatic chemicals and specialty chemicals, strengthening its presence across Brazil and the broader Latin American market.

Performance

Q1 FY27:

1. Revenue from operations: ₹98.85 crs (↑12.80% YoY)
2. EBITDA: ₹3.31 crs | EBITDA Margin: 3.34% (↓1,361 Bps)
3. PAT: -₹8.14 crs | PAT Margin: -8.23% (↓1,729 Bps)

FY26:

1. Revenue from operations: ₹366.47 crs
2. EBITDA: ₹40.75 crs | EBITDA Margin: 11.12%
3. PAT: ₹0.76 crs | PAT Margin: 0.21%